1.1 Research Scope 1.2 Market Segmentation 1.3 Research Objectives 1.4 Research Methodology 1.4.1 Research Process 1.4.2 Data Triangulation 1.4.3 Research Approach 1.4.4 Base Year 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.5.2 Covid-19 Impact: Commodity Prices Indices 1.5.3 Covid-19 Impact: Global Major Government Policy 1.6 The Covid-19 Impact on Neuroendocrine Carcinoma Drugs Industry 1.7 COVID-19 Impact: Neuroendocrine Carcinoma Drugs Market Trends 2 Global Neuroendocrine Carcinoma Drugs Quarterly Market Size Analysis 2.1 Neuroendocrine Carcinoma Drugs Business Impact Assessment - COVID-19 2.1.1 Global Neuroendocrine Carcinoma Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.1.2 Global Neuroendocrine Carcinoma Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.2 Global Neuroendocrine Carcinoma Drugs Quarterly Market Size 2020-2021 2.3 COVID-19-Driven Market Dynamics and Factor Analysis 2.3.1 Drivers 2.3.2 Restraints 2.3.3 Opportunities 2.3.4 Challenges 3 Quarterly Competitive Assessment, 2020 3.1 Global Neuroendocrine Carcinoma Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020 3.2 Global Neuroendocrine Carcinoma Drugs Factory Price by Manufacturers 3.3 Location of Key Manufacturers Neuroendocrine Carcinoma Drugs Manufacturing Factories and Area Served 3.4 Date of Key Manufacturers Enter into Neuroendocrine Carcinoma Drugs Market 3.5 Key Manufacturers Neuroendocrine Carcinoma Drugs Product Offered 3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Neuroendocrine Carcinoma Drugs Segments, By Type 4.1 Introduction 1.4.1 Somatostatin Analogs 1.4.2 Targeted Therapy 1.4.3 Chemotherapy 4.2 By Type, Global Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 4.2.1 By Type, Global Neuroendocrine Carcinoma Drugs Market Size by Type, 2020-2021 4.2.2 By Type, Global Neuroendocrine Carcinoma Drugs Price, 2020-2021 5 Impact of Covid-19 on Neuroendocrine Carcinoma Drugs Segments, By Application 5.1 Overview 5.5.1 Hospital 5.5.2 Clinics 5.5.3 Oncology Centres 5.5.4 Ambulatory Surgery Centres 5.2 By Application, Global Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 5.2.1 By Application, Global Neuroendocrine Carcinoma Drugs Market Size by Application, 2019-2021 5.2.2 By Application, Global Neuroendocrine Carcinoma Drugs Price, 2020-2021 6 Geographic Analysis 6.1 Introduction 6.2 North America 6.2.1 Macroeconomic Indicators of US 6.2.2 US 6.2.3 Canada 6.3 Europe 6.3.1 Macroeconomic Indicators of Europe 6.3.2 Germany 6.3.3 France 6.3.4 UK 6.3.5 Italy 6.4 Asia-Pacific 6.4.1 Macroeconomic Indicators of Asia-Pacific 6.4.2 China 6.4.3 Japan 6.4.4 South Korea 6.4.5 India 6.4.6 ASEAN 6.5 Rest of World 6.5.1 Latin America 6.5.2 Middle East and Africa 7 Company Profiles 7.1 Xiaflex 7.1.1 Xiaflex Business Overview 7.1.2 Xiaflex Neuroendocrine Carcinoma Drugs Quarterly Production and Revenue, 2020 7.1.3 Xiaflex Neuroendocrine Carcinoma Drugs Product Introduction 7.1.4 Xiaflex Response to COVID-19 and Related Developments 7.2 Novartis AG 7.2.1 Novartis AG Business Overview 7.2.2 Novartis AG Neuroendocrine Carcinoma Drugs Quarterly Production and Revenue, 2020 7.2.3 Novartis AG Neuroendocrine Carcinoma Drugs Product Introduction 7.2.4 Novartis AG Response to COVID-19 and Related Developments 7.3 Roche 7.3.1 Roche Business Overview 7.3.2 Roche Neuroendocrine Carcinoma Drugs Quarterly Production and Revenue, 2020 7.3.3 Roche Neuroendocrine Carcinoma Drugs Product Introduction 7.3.4 Roche Response to COVID-19 and Related Developments 7.4 Molecular Insight pharmaceuticals 7.4.1 Molecular Insight pharmaceuticals Business Overview 7.4.2 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Quarterly Production and Revenue, 2020 7.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Introduction 7.4.4 Molecular Insight pharmaceuticals Response to COVID-19 and Related Developments 7.5 Callisto Pharmaceuticals 7.5.1 Callisto Pharmaceuticals Business Overview 7.5.2 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Quarterly Production and Revenue, 2020 7.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Introduction 7.5.4 Callisto Pharmaceuticals Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis 8.1 Neuroendocrine Carcinoma Drugs Supply Chain Analysis 8.1.1 Neuroendocrine Carcinoma Drugs Supply Chain Analysis 8.1.2 Covid-19 Impact on Neuroendocrine Carcinoma Drugs Supply Chain 8.2 Distribution Channels Analysis 8.2.1 Neuroendocrine Carcinoma Drugs Distribution Channels 8.2.2 Covid-19 Impact on Neuroendocrine Carcinoma Drugs Distribution Channels 8.2.3 Neuroendocrine Carcinoma Drugs Distributors 8.3 Neuroendocrine Carcinoma Drugs Customers 9 Key Findings 10 Appendix 10.1 About Us 10.2 Disclaimer

List of Tables Table 1. Overview of the World Economic Outlook Projections Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity) Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) Table 7. Covid-19 Impact: Global Major Government Policy Table 8. The Covid-19 Impact on Neuroendocrine Carcinoma Drugs Assessment Table 9. COVID-19 Impact: Neuroendocrine Carcinoma Drugs Market Trends Table 10. COVID-19 Impact Global Neuroendocrine Carcinoma Drugs Market Size Table 11. Global Neuroendocrine Carcinoma Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K MT) Table 12. Global Neuroendocrine Carcinoma Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/MT) Table 13. Global Neuroendocrine Carcinoma Drugs Quarterly Market Size, 2020 (US$ Million) & (K MT) Table 14. Global Neuroendocrine Carcinoma Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million) Table 15. Global Neuroendocrine Carcinoma Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K MT) Table 16. Global Neuroendocrine Carcinoma Drugs Market Growth Drivers Table 17. Global Neuroendocrine Carcinoma Drugs Market Restraints Table 18. Global Neuroendocrine Carcinoma Drugs Market Opportunities Table 19. Global Neuroendocrine Carcinoma Drugs Market Challenges Table 20. Key Manufacturers Neuroendocrine Carcinoma Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million) Table 21. Top Manufacturers, Neuroendocrine Carcinoma Drugs Market Size, 2019 (K MT) & (US$ Million) Table 22. Neuroendocrine Carcinoma Drugs Factory Price by Manufacturers 2020 (USD/MT) Table 23. Location of Key Manufacturers Neuroendocrine Carcinoma Drugs Manufacturing Plants Table 24. Key Manufacturers Neuroendocrine Carcinoma Drugs Market Served Table 25. Date of Key Manufacturers Enter into Neuroendocrine Carcinoma Drugs Market Table 26. Key Manufacturers Neuroendocrine Carcinoma Drugs Product Type Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Neuroendocrine Carcinoma Drugs Market Size by Type, 2020, (US$ Million) Table 29. Global Neuroendocrine Carcinoma Drugs Market Size by Type, 2020 (K MT) Table 30. Global Neuroendocrine Carcinoma Drugs Price: by Type, 2020-2021 (USD/MT) Table 31. Global Neuroendocrine Carcinoma Drugs Market Size by Application: 2020-2021 (US$ Million) Table 32. Global Neuroendocrine Carcinoma Drugs Market Size by Application, 2020-2021 (K MT) Table 33. Global Neuroendocrine Carcinoma Drugs Price: by Application, 2020-2021 (USD/MT) Table 34. Global Neuroendocrine Carcinoma Drugs Market Size by Region, 2019-2021 (US$ Million) Table 35. Global Neuroendocrine Carcinoma Drugs Market Size by Region, 2019-2021 (K MT) Table 36. By Country, North America Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) Table 37. By Country, North America Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (K MT) Table 38. US Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 39. Canada Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy) Table 41. By Country, Europe Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) Table 42. By Country, Europe Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (K MT) Table 43. Germany Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 44. France Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 45. UK Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 46. Italy Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN) Table 48. By Region, Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) Table 49. By Region, Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (K MT) Table 50. China Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 51. Japan Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 52. South Korea Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 53. India Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 54. ASEAN Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 55. Latin America Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 56. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size, 2019-2021 (US$ Million) & (K MT) Table 57. Xiaflex Business Overview Table 58. Xiaflex Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 59. Xiaflex Neuroendocrine Carcinoma Drugs Product Table 60. Xiaflex Response to COVID-19 and Related Developments Table 61. Novartis AG Business Overview Table 62. Novartis AG Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 63. Novartis AG Neuroendocrine Carcinoma Drugs Product Table 64. Novartis AG Response to COVID-19 and Related Developments Table 65. Roche Business Overview Table 66. Roche Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 67. Roche Neuroendocrine Carcinoma Drugs Product Table 68. Roche Response to COVID-19 and Related Developments Table 69. Molecular Insight pharmaceuticals Business Overview Table 70. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 71. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Table 72. Molecular Insight pharmaceuticals Response to COVID-19 and Related Developments Table 73. Callisto Pharmaceuticals Business Overview Table 74. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020 Table 75. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Table 76. Callisto Pharmaceuticals Response to COVID-19 and Related Developments Table 77. Neuroendocrine Carcinoma Drugs Distributors List Table 78. Neuroendocrine Carcinoma Drugs Customers List Table 79. Covid-19 Impact on Neuroendocrine Carcinoma Drugs Customers List of Figures Figure 1. Neuroendocrine Carcinoma Drugs Product Picture Figure 2. Neuroendocrine Carcinoma Drugs Market Segmentation Figure 3. Research Objectives Figure 4. Research Process Figure 5. Data Triangulation Figure 6. Research Approach Figure 7. Commodity Prices-Metals Price Indices Figure 8. Commodity Prices- Precious Metal Price Indices Figure 9. Commodity Prices- Agricultural Raw Material Price Indices Figure 10. Commodity Prices- Food and Beverage Price Indices Figure 11. Commodity Prices- Fertilizer Price Indices Figure 12. Commodity Prices- Energy Price Indices Figure 13. G20+: Economic Policy Responses to COVID-19 Figure 14. Global Neuroendocrine Carcinoma Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million) Figure 15. Global Neuroendocrine Carcinoma Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%) Figure 16. Global Neuroendocrine Carcinoma Drugs Market Size, Quarterly Growth, 2020-2021 (%) Figure 17. Global Neuroendocrine Carcinoma Drugs Market Size, Market Share by Type, 2019 VS 2020 (%) Figure 18. Global Neuroendocrine Carcinoma Drugs Market Size, Market Share by Application, 2019 VS 2020 (%) Figure 19. Global Neuroendocrine Carcinoma Drugs Market Size Market Share by Region, 2019 VS 2020 (%) Figure 20. United States Composite PMI and GDP Figure 21. Eurozone Composite PMI and GDP Figure 22. Eurozone Core v. Periphery PMI Output Indices Figure 23. Core v. Periphery PMI Employment Indices Figure 24. UK Composite PMI and GDP Figure 25. Caixin China Composite Output Index Figure 26. Caixin China General Services Business Activity Index Figure 27. Japan Composite Output Index Figure 28. South Korea Manufacturing PMI Figure 29. India Composite Output Index Figure 30. ASEAN Manufacturing PMI Figure 31. By Region, Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size Market Share, 2019-2021

Xiaflex Novartis AG Roche Molecular Insight pharmaceuticals Callisto Pharmaceuticals